MedPath
HSA Approval

BISLAN TABLET 8 mg

SIN10582P

BISLAN TABLET 8 mg

BISLAN TABLET 8 mg

December 22, 1998

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantYUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD
Licence HolderYUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

R05CB02

bromhexine

Manufacturer Information

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Y S P INDUSTRIES (M) SDN BHD

Active Ingredients

BROMHEXINE HCl

8 mg

Bromhexine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BISLAN TABLET 8 mg - HSA Approval | MedPath